Cat. #152781
Anti-BAG3 [V65P1E8*D2]
Cat. #: 152781
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 3-5 days
Target: BAG family molecular chaperone regulator 3
Class: Monoclonal
Application: ELISA ; IHC ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ayham Alnabulsi
Institute: Vertebrate Antibodies Limited
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-BAG3 [V65P1E8*D2]
- Alternate name: BAG3, Bcl-2-associated athanogene 3, Bcl-2-binding protein Bis, Docking protein CAIR-1
- Clone: V65P1E8*D2
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: ELISA ; IHC ; WB
- Description: Anti-BCL2-Associated Athanogene 3 (BAG3) [V65P1E8*D2] is specific for human BAG3. BAG3 is involved in chaperone-assisted selective autophagy. Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. In muscle cells, BAG3 cooperates with the molecular chaperones Hsc70 and HspB8 to induce the degradation of mechanically damaged cytoskeleton components in lysosomes. This process is called chaperone-assisted selective autophagy (CASA) and is essential for maintaining muscle activity. Defects in BAG3 are the cause of myopathy myofibrillar BAG3-related (MFM-BAG3) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients.
- Immunogen: Ovalbumin-conjugated synthetic peptide MTDTPGNPAAP
- Isotype: IgG1 kappa
- Myeloma used: P3X63Ag8.653
Target Details
- Target: BAG family molecular chaperone regulator 3
- Target background: Anti-BCL2-Associated Athanogene 3 (BAG3) [V65P1E8*D2] is specific for human BAG3. BAG3 is involved in chaperone-assisted selective autophagy. Inhibits the chaperone activity of HSP70/HSC70 by promoting substrate release. Has anti-apoptotic activity. In muscle cells, BAG3 cooperates with the molecular chaperones Hsc70 and HspB8 to induce the degradation of mechanically damaged cytoskeleton components in lysosomes. This process is called chaperone-assisted selective autophagy (CASA) and is essential for maintaining muscle activity. Defects in BAG3 are the cause of myopathy myofibrillar BAG3-related (MFM-BAG3) [MIM:612954]. A neuromuscular disorder that results in early-onset, severe, progressive, diffuse muscle weakness associated with cardiomyopathy, severe respiratory insufficiency during adolescence, and a rigid spine in some patients.
Applications
- Application: ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C